leukemias	are	blood cancers
leukemias	include	acute myeloid leukemia
leukemias	include	acute lymphoblastic leukemia
leukemias	include	chronic myeloid leukemia
leukemias	include	chronic lymphocytic leukemia
leukemias	arise from	hematopoietic stem cells
leukemias	present with	fatigue
leukemias	present with	fever
leukemias	present with	night sweats
leukemias	cause	anemia
leukemias	cause	thrombocytopenia
leukemias	cause	neutropenia
leukemias	increase risk of	infections
leukemias	associated with	bleeding tendency
down syndrome	increases risk of	acute lymphoblastic leukemia
fanconi anemia	increases risk of	acute myeloid leukemia
benzene exposure	increases risk of	leukemia
ionizing radiation	increases risk of	leukemia
prior chemotherapy	increases risk of	treatment-related leukemia
t(9;22) translocation	is associated with	chronic myeloid leukemia
philadelphia chromosome	is associated with	chronic myeloid leukemia
bcr-abl fusion	is characteristic of	chronic myeloid leukemia
acute lymphoblastic leukemia	responds to	corticosteroids
acute myeloid leukemia	treated with	cytarabine
acute myeloid leukemia	treated with	daunorubicin
acute promyelocytic leukemia	treated with	all-trans retinoic acid
all-trans retinoic acid	is a	differentiation agent
imatinib	treats	chronic myeloid leukemia
dasatinib	treats	chronic myeloid leukemia
nilotinib	treats	chronic myeloid leukemia
bone marrow transplant	is used for	leukemia
allogeneic stem cell transplant	is used for	high-risk leukemia
autologous stem cell transplant	used for	relapsed leukemia
cytarabine	is a	chemotherapy agent
daunorubicin	is a	chemotherapy agent
etoposide	is a	chemotherapy agent
cyclophosphamide	is a	chemotherapy agent
maintenance therapy	used for	acute lymphoblastic leukemia remission
intrathecal chemotherapy	used for	CNS prophylaxis in leukemia
flow cytometry	used for	leukemia subclassification
cytogenetics	used for	leukemia risk stratification
polymerase chain reaction	detects	minimal residual disease
minimal residual disease	predicts	relapse risk
cytogenetic abnormality	guides	prognosis in leukemia
tissue biopsy	provides	leukemia diagnosis
bone marrow biopsy	confirms	leukemia diagnosis
white blood cell count	abnormal in	leukemia
neutrophil count	low in	leukemia
platelet count	low in	leukemia
coagulopathy	associated with	leukemia
DIC	occurs in	acute promyelocytic leukemia
DIC	leads to	bleeding
neutropenia	predisposes to	infection
infections	lead to	hospitalization
graft-versus-host disease	is a complication of	allogeneic stem cell transplant
transplant-related mortality	is reduced by	HLA matching
HLA matching	essential for	allogeneic transplantation
HLA mismatch	increases risk of	graft-versus-host disease
risk stratification	informs	treatment intensity in leukemia
age	influences	leukemia prognosis
performance status	influences	treatment choice in leukemia
cytogenetic risk	correlates with	survival in leukemia
mutational status	influences	targeted therapy choice
FLT3 mutation	associated with	poor prognosis
NPM1 mutation	associated with	favorable prognosis
TP53 mutation	associated with	poor prognosis
core-binding factor leukemia	has	favorable prognosis
BCL2 overexpression	associated with	leukemia phenotype
hypomethylating agent	used for	AML in elderly
azacitidine	is a	hypomethylating agent
decitabine	is a	hypomethylating agent
venetoclax	used for	AML treatment
IDH1 mutation	targeted by	ivosidenib
IDH2 mutation	targeted by	enasidenib
AML treated with	venetoclax-based therapy
CML	treated with	tyrosine kinase inhibitors
tyrosine kinase inhibitors	used for	CML
imatinib	is a	BCR-ABL tyrosine kinase inhibitor
dasatinib	is a	BCR-ABL tyrosine kinase inhibitor
nilotinib	is a	BCR-ABL tyrosine kinase inhibitor
CML progresses to	blast crisis
blast crisis	marks	disease progression in CML
CNS leukemia	involves	central nervous system
intrathecal methotrexate	used for	CNS leukemia
CNS leukemia	worsens	prognosis
opportunistic infections	occur in	leukemia patients on chemotherapy
neutropenic fever	presents in	leukemia therapy
granulocyte colony-stimulating factor	used for	neutropenia management
G-CSF	reduces	febrile neutropenia
febrile neutropenia	increases	hospitalization duration
pancytopenia	seen in	leukemia
pancytopenia	results in	fatigue
transfusion	supports	leukemia treatment
platelet transfusion	treats	bleeding risk in leukemia
red blood cell transfusion	treats	anemia in leukemia
complex karyotype	associated with	poor prognosis in AML
relapse	occurs after	remission
induction therapy	aims for	remission
MRD status	guides	prognosis
